miércoles, 22 de mayo de 2019
NCCN Roundtable: Ensuring Patient Access to Innovative Cancer Therapies
On March 21, 2019, as part of its 2019 Annual Conference, NCCN featured the following session, NCCN Roundtable Discussion: Emerging Issues in Oncology – Ensuring Access to, and Delivery of, Innovative Therapies and Patient Centered Care in Oncology. Experts discussed the impact the high cost of care is having on health systems and patient access to costly immunotherapies.
Moderator: Clifford Goodman, PhD, Senior Vice President, The Lewin Group
Stefanie Joho, Survivor, Health Advocate, and Consultant
Frederick L. Locke, MD, Moffitt Cancer Center
Jennifer Malin, MD, PhD, UnitedHealth Group
John W. Sweetenham, MD, Huntsman Cancer Institute at the University of Utah
Lalan S. Wilfong, MD, Texas Oncology
Supported by Abbvie; Astellas; AstraZeneca; Celgene Corporation; Eisai Inc.; Foundation Medicine; Gilead Sciences Inc; Halozyme; Janssen; Karyopharm Therapeutics Inc.; Loxo Oncology; Novartis; Pharmacyclics, an AbbVie Company; and Sanofi-Genzyme. Sponsored by Bristol-Myers Squibb.